PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C

被引：0
作者：
Ideo, G
Giuseppe, S
Attili, A
Chirianni, A
Craxi, A
Di Perri, G
Picciotto, A
Rizzetto, M
Ruggiero, G
Suter, F
Sarracino, M
机构：
[1] Osped S Giuseppe, Dept Hepatol, Milan, Italy
[2] Univ Roma La Sapienza, Dept Gastroenterol, Rome, Italy
[3] Cotugno Hosp, Dept Infectious, Naples, Italy
[4] Univ Palermo, Dept Gastroenterol, Palermo, Italy
[5] Savoia Hosp, Dept Infect Amedeo, Turin, Italy
[6] Hepatitis Diagnosis & Therapy, Genoa, Italy
[7] Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, I-10126 Turin, Italy
[8] Univ Naples, Dept Med & Hepatol, Naples, Italy
[9] Spedali Riumti, Dept Infect Dis, Bergamo, Italy
[10] Roche SPA, Monza, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1630
引用
收藏
页码：570A / 570A
页数：1
相关论文
共 50 条
[21]   Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). [J].
Ferenci, P ;
Shiffman, ML ;
Fried, MW ;
Sulkowski, MS ;
Haeussinger, D ;
Zarski, JP ;
Goncales, F ;
Jensen, DM ;
Bonino, F ;
Dhumeaux, D ;
Blotner, S ;
Hoffman, J ;
Oliveto, J .
HEPATOLOGY, 2001, 34 (04) :351A-351A
[22]   Ribavirin (RBV) dose reduction in patients with HCV genotype 1 infection receiving combination treatment with peginterferon alfa-2a (40kd) (Pegasys®) plus RBV (Copegus®) [J].
Lee, JS ;
Hu, S ;
Lopez-Talavera, JC ;
Hoffmann-La Roche, F .
HEPATOLOGY, 2004, 40 (04) :335A-335A
[23]   Differences between genotype 1 patients with SVR or relapse after treatment for chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) [J].
Zehnter, Elmar ;
Mauss, Stefan ;
Beoker, Klaus ;
Thomas, Lutz ;
Racky, Stefan ;
Schmidt, Wolfgang ;
Ullrich, Rainer ;
Sbrijer, Innessa ;
Heyne, Renate ;
Schober, Andreas ;
John, Christine ;
Hey, Karl-Heinz ;
Bokemeyer, Bernd ;
Kallinowski, Birgit ;
Moeller, Bernd ;
Pape, Stefan ;
Alshuth, Ulrich ;
Hueppe, Dietrich .
GASTROENTEROLOGY, 2007, 132 (04) :A789-A789
[24]   The cost-effectiveness of peginterferon alfa-2a (40kd) (PEGASYS) plus ribavirin (COPEGUS) vs. interferon alfa-2b plus ribavirin for chronic hepatitis C (CHC) [J].
Sullivan, SD ;
Green, J ;
Patel, KK ;
Craxi, A ;
Alberti, A ;
Giuliani, G ;
De Carli, C .
VALUE IN HEALTH, 2003, 6 (03) :262-263
[25]   Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions [J].
Hueppe, Dietrich ;
Zehnter, Elmar ;
Mauss, Stefan ;
Kaiser, Stephan ;
Schober, Andreas ;
Schuchmann, Marcus ;
Boeker, Klaus ;
Moog, Gero ;
Schiffelholz, Willibold ;
Pape, Stefan ;
Heyne, Renate ;
Ackermann, Frank ;
Schmidt, Wolfgang ;
John, Christine ;
Lohmeyer, Juergen ;
Hey, Karl-Heinz ;
Alshuth, Ulrich .
GASTROENTEROLOGY, 2009, 136 (05) :A839-A840
[26]   Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy [J].
Sherman, M. ;
Yoshida, E. M. ;
Deschenes, M. ;
Krajden, M. ;
Bain, V. G. ;
Peltekian, K. ;
Anderson, F. ;
Kaita, K. ;
Simonyi, S. ;
Balshaw, R. ;
Lee, S. S. .
GUT, 2006, 55 (11) :1631-1638
[27]   QoL benefits observed as early as week 2 with peginterferon alfa-2a (40KD) (pegasys) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV [J].
Hassanien, TI ;
Cooksley, WGE ;
Sulkowski, M ;
Smith, C ;
Marinos, G ;
Lai, MY ;
Pastore, G ;
Trejo-Estrada, R ;
Horta, A ;
Vale, E ;
Wintfeld, NS ;
Neary, M ;
Green, J .
JOURNAL OF HEPATOLOGY, 2002, 36 :110-110
[28]   Randomized, controlled, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) and amantadine (AMA) or placebo in patients with chronic hepatitis C genotype 1 infection. [J].
Ferenci, P ;
Formann, E ;
Laferl, H ;
Gschwantler, M ;
Hackl, F ;
Brunner, H ;
Datz, C ;
Stauber, R ;
Munda, P ;
Gangl, A .
HEPATOLOGY, 2004, 40 (04) :396A-396A
[29]   Safety and adherence to peginterferon alfa-2a (40KD) plus ribavirin (RBV) in black Americans with chronic hepatitis C (CHC) HCV genotype 1 [J].
Howell, CD ;
Jeffers, LS ;
Hu, S ;
Lopez-Talavera, JC .
GASTROENTEROLOGY, 2004, 126 (04) :A722-A723
[30]   Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin in chronic hepatitis C:: Retreatment of patients who relapsed virologically after 24 weeks of therapy. [J].
Goncales, F ;
Bernstein, DE ;
Berg, C ;
Sette, H ;
Rasenack, J ;
Diago, M ;
Jensen, DM ;
Cooksley, WGE ;
Roberts, P ;
Ackrill, AM .
HEPATOLOGY, 2002, 36 (04) :361A-361A
12345